Dr Reddys Laboratories Stock Current Valuation
| RDDA Stock | EUR 14.60 0.30 2.10% |
Valuation analysis of Dr Reddys Laboratories helps investors to measure Dr Reddys' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Dr Reddys' price fluctuation is very steady at this time. Calculation of the real value of Dr Reddys Laboratories is based on 3 months time horizon. Increasing Dr Reddys' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the RDDA stock is determined by what a typical buyer is willing to pay for full or partial control of Dr Reddys Laboratories. Since Dr Reddys is currently traded on the exchange, buyers and sellers on that exchange determine the market value of RDDA Stock. However, Dr Reddys' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.6 | Real 14.33 | Hype 14.6 | Naive 14.77 |
The real value of RDDA Stock, also known as its intrinsic value, is the underlying worth of Dr Reddys Laboratories Company, which is reflected in its stock price. It is based on Dr Reddys' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Dr Reddys' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Dr Reddys Laboratories helps investors to forecast how RDDA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dr Reddys more accurately as focusing exclusively on Dr Reddys' fundamentals will not take into account other important factors: Dr Reddys Laboratories Company Current Valuation Analysis
Dr Reddys' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Dr Reddys Current Valuation | 8.47 B |
Most of Dr Reddys' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Dr Reddys Laboratories has a Current Valuation of 8.47 B. This is 41.06% lower than that of the Healthcare sector and 13.86% higher than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all Germany stocks is 49.08% higher than that of the company.
RDDA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is rated below average in current valuation category among its peers.
RDDA Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0949 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 8.47 B | |||
| Shares Outstanding | 166.1 M | |||
| Shares Owned By Institutions | 10.37 % | |||
| Price To Earning | 23.95 X | |||
| Price To Book | 3.61 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 214.39 B | |||
| Gross Profit | 113.84 B | |||
| EBITDA | 48.86 B | |||
| Net Income | 23.57 B | |||
| Cash And Equivalents | 306.55 M | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 5.75 B | |||
| Debt To Equity | 23.50 % | |||
| Current Ratio | 1.89 X | |||
| Book Value Per Share | 1,326 X | |||
| Cash Flow From Operations | 28.11 B | |||
| Earnings Per Share | 2.47 X | |||
| Price To Earnings To Growth | 1.50 X | |||
| Target Price | 77.85 | |||
| Number Of Employees | 24.8 K | |||
| Beta | 0.24 | |||
| Market Capitalization | 8.14 B | |||
| Total Asset | 296.65 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.71 % | |||
| Net Asset | 296.65 B | |||
| Last Dividend Paid | 30.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in RDDA Stock
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.